Itamar Medical Ltd represents values of innovation, commitment to patient care, and technological advancements in the medical industry. The company's corporate philosophy focuses on providing cutting-edge solutions for the diagnosis and management of sleep apnea and other related sleep disorders. By leveraging their expertise and advanced technology, Itamar Medical Ltd aims to improve the lives of patients worldwide suffering from sleep-related conditions. With a strong emphasis on research and development, the company continuously strives to deliver high-quality and reliable products that address the unique needs of healthcare professionals and patients alike.

Itamar Medical Ltd is primarily present in the following countries and regions: United States, Israel, Europe, and Asia.

Itamar Medical Ltd has achieved several significant milestones. The company developed the WatchPAT™ home sleep apnea test, which revolutionized the way sleep disorders are diagnosed. It also introduced the EndoPAT™ device for assessing endothelial function, helping in the detection and prevention of cardiovascular diseases. Itamar Medical has received various regulatory approvals and certifications for its products, expanding its global reach. Additionally, the company has established strategic partnerships with key players in the healthcare industry, further enhancing its market position. Through its innovative solutions and collaborations, Itamar Medical Ltd continues to make important strides in improving sleep and cardiovascular health.

Itamar Medical Ltd is a renowned global medical technology company that focuses on the development, marketing, and distribution of medical devices for the diagnosis of sleep apnea and other sleep disorders. Founded in 1997, Itamar Medical has established itself as a leader in the field, providing innovative solutions backed by rigorous research and development. The company's flagship product, WatchPAT, is a cutting-edge diagnostic device that offers a convenient at-home alternative to traditional sleep studies. With its commitment to improving patients' lives and enhancing healthcare professionals' understanding of sleep-related conditions, Itamar Medical has gained recognition and trust worldwide.

The main competitors of Itamar Medical Ltd in the market include leading companies such as ResMed Inc., Koninklijke Philips N.V., and Natus Medical Incorporated.

Itamar Medical Ltd is primarily active in the healthcare industry.

The business model of Itamar Medical Ltd revolves around the development, manufacturing, and marketing of non-invasive medical devices for sleep apnea diagnosis and management. Itamar Medical specializes in creating innovative products that assist in the diagnosis of various sleep disorders, with a particular focus on obstructive sleep apnea. The company's flagship product, WatchPAT, is a portable and user-friendly diagnostic device that measures various physiological parameters during sleep, providing accurate and reliable results. Itamar Medical aims to enhance patient care by providing healthcare professionals with advanced diagnostic tools that improve the management and treatment of sleep-related disorders, ultimately improving patients' quality of life.

KGV kan i øjeblikket ikke beregnes for Itamar Medical.

KUV kan i øjeblikket ikke beregnes for Itamar Medical.

AlleAktien Kvalitetsscore for Itamar Medical er 6/10.

Omsætningen kan i øjeblikket ikke beregnes for Itamar Medical.

Overskuddet kan i øjeblikket ikke beregnes for Itamar Medical.

Itamar Medical Ltd is an Israeli company that specializes in the development and manufacturing of medical devices for the diagnosis and monitoring of sleep disorders and cardiovascular diseases. The business model of Itamar Medical is based on providing innovative technologies and solutions for the healthcare industry to improve patient's quality of life and optimize medical care. One of the main divisions of Itamar Medical is sleep medicine, where the company offers a wide range of products. This includes specialized EEG sensors like the NightWatch system, which enables easy and effective monitoring of patients. Itamar Medical also offers a home screening service for sleep-related breathing disorders, where patients are sent a portable device to monitor their sleep quality. Another important segment of Itamar Medical is cardiology, where the company offers innovative devices for the diagnosis and monitoring of cardiovascular diseases. This includes the EndoPAT system, which allows doctors to measure the function of blood vessels in patients. This is an important indicator for the presence of atherosclerosis and other heart diseases. Itamar Medical also focuses on the field of clinical information systems (CIS). The company develops medical IT solutions to optimize workflows in hospitals and doctor's offices. Itamar Medical's CIS solutions help doctors and hospital staff effectively manage patient data and make critical data quickly accessible when needed. The business model of Itamar Medical is based on the development of groundbreaking technologies that advance medical progress. The company also strives for high user-friendliness and an easily accessible user interface to enable easy integration into existing systems. By collaborating with public and private healthcare institutions, Itamar Medical can offer its products and services worldwide, thus meeting the need for effective medical care. Overall, Itamar Medical has established itself as an important player in the healthcare industry by providing innovative solutions to some of the most common medical challenges. The business model includes a wide range of products and services tailored to the needs of patients and medical professionals. Whether it's sleep disorders, cardiovascular diseases, or medical IT solutions, Itamar Medical aims to improve the quality of life for patients worldwide.

Itamar Medical udbetaler et udbytte på 0 USD fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Itamar Medical, eller selskabet udbetaler ikke udbytte.

ISIN'en for Itamar Medical er IL0011024580.

WKN for Itamar Medical er A1CZAF.

Tickeren for Itamar Medical er ITMR.TA.

I løbet af de sidste 12 måneder betalte Itamar Medical en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Itamar Medical sandsynligvis betale en dividende på 0 USD.

Udbytteafkastet for Itamar Medical er i øjeblikket .

Itamar Medical betaler kvartalsvis udbytte. Dette uddeles i månederne .

Itamar Medical betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 USD. Dette svarer til et dividendeafkast på 0 %.

Itamar Medical bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Itamar Medical fra den 21.9.2024 på 0 USD, skulle du have haft aktien i din portefølje før ex-datoen den 21.9.2024.

Udbetalingen af det sidste udbytte blev foretaget den 21.9.2024.

I løbet af 2023 udbetalte Itamar Medical 0 USD i form af dividender.

Udbytterne fra Itamar Medical udbetales i USD.